There are 2867 resources available
793P - NeoPeLe: A phase II trial of neoadjuvant (NAT) pembrolizumab (Pembro) combined with lenvatinib (Lenva) in resectable stage III melanoma
Presenter: Georgina Long
Session: Poster session 03
1064P - Genomic characterization of first line advanced or metastatic non-small cell lung cancer (aNSCLC) patients (pts) subgroups associated with good/bad prognosis
Presenter: Mariano Provencio Pulla
Session: Poster session 15
1407P - Real-world outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) and tumors with androgen receptor (<italic>AR</italic>) 878/875 mutations
Presenter: Tyler Stewart
Session: Poster session 11
794P - Efficacy and tolerability of neoadjuvant treatment with T-VEC in difficult to resect primary basal cell carcinoma: A phase II clinical trial (NeoBCC)
Presenter: Julia Ressler
Session: Poster session 03
1065P - The impact of pre-treatment plasma sex hormones on the immune checkpoint inhibitors response in patients with metastatic non-small cell lung cancer
Presenter: Yumeng Zhang
Session: Poster session 15
1408P - Comparative transcriptomic analyses of 100,691 primary tumors from East Asian (EA) and North American (NA) men with prostate cancer (PCa)
Presenter: Melvin Lee Kiang Chua
Session: Poster session 11
795P - A phase Ib trial of neoadjuvant oncolytic virus OrienX010 (ori) and anti-PD-1 toripalimab (tori) combo in patients (pts) with resectable stage IIIb-IV (M1a) acral melanoma
Presenter: Xiaoting Wei
Session: Poster session 03
1066P - Tumor microenvironment (TME) of HRAS mutated non-small cell lung cancer (NSCLC)
Presenter: Asaad Trabolsi
Session: Poster session 15
1409P - Development of a clinically accessible, circulating prognostic lipid biomarker panel in men with mCRPC to guide potential metabolic intervention
Presenter: Tahlia Scheinberg
Session: Poster session 11